These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 25260897

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
    Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, Descamps V, Hober D, Dubuisson J, Rouillé Y, Séron K.
    Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
    [Abstract] [Full Text] [Related]

  • 3. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry.
    Ciesek S, von Hahn T, Colpitts CC, Schang LM, Friesland M, Steinmann J, Manns MP, Ott M, Wedemeyer H, Meuleman P, Pietschmann T, Steinmann E.
    Hepatology; 2011 Dec; 54(6):1947-55. PubMed ID: 21837753
    [Abstract] [Full Text] [Related]

  • 4. Epigallocatechin gallate inhibits hepatitis B virus infection in human liver chimeric mice.
    Lai YH, Sun CP, Huang HC, Chen JC, Liu HK, Huang C.
    BMC Complement Altern Med; 2018 Sep 06; 18(1):248. PubMed ID: 30189898
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Strategies to inhibit entry of HBV and HDV into hepatocytes.
    Urban S, Bartenschlager R, Kubitz R, Zoulim F.
    Gastroenterology; 2014 Jul 06; 147(1):48-64. PubMed ID: 24768844
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro.
    Xu J, Wang J, Deng F, Hu Z, Wang H.
    Antiviral Res; 2008 Jun 06; 78(3):242-9. PubMed ID: 18313149
    [Abstract] [Full Text] [Related]

  • 10. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.
    Iwamoto M, Watashi K, Tsukuda S, Aly HH, Fukasawa M, Fujimoto A, Suzuki R, Aizaki H, Ito T, Koiwai O, Kusuhara H, Wakita T.
    Biochem Biophys Res Commun; 2014 Jan 17; 443(3):808-13. PubMed ID: 24342612
    [Abstract] [Full Text] [Related]

  • 11. Unusual Features of Sodium Taurocholate Cotransporting Polypeptide as a Hepatitis B Virus Receptor.
    Li J, Zong L, Sureau C, Barker L, Wands JR, Tong S.
    J Virol; 2016 Sep 15; 90(18):8302-13. PubMed ID: 27384660
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Interleukin 6 inhibits HBV entry through NTCP down regulation.
    Bouezzedine F, Fardel O, Gripon P.
    Virology; 2015 Jul 15; 481():34-42. PubMed ID: 25765005
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. (-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus.
    Chen C, Qiu H, Gong J, Liu Q, Xiao H, Chen XW, Sun BL, Yang RG.
    Arch Virol; 2012 Jul 15; 157(7):1301-12. PubMed ID: 22491814
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity.
    Wang XJ, Hu W, Zhang TY, Mao YY, Liu NN, Wang SQ.
    Antiviral Res; 2015 Aug 15; 120():140-6. PubMed ID: 26086883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.